Evidence of the extrathymic development of tyrosinase-related protein-2-recognizing CD8+ T cells with low avidity

Immunology

Volumn 104, Issue 1, 2001, Pages 67-74

  Harada, Mamoru ^a,b   Yamada, Hisakata ^a   Tatsugami, Katsunori ^a   Nomoto, Kikuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR BETA; TUMOR ANTIGEN; TYROSINASE RELATED PROTEIN 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY AFFINITY; ANTIGEN DETECTION; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOREACTIVITY; LYMPHOCYTE DIFFERENTIATION; MELANOCYTE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROLYMPHOCYTE; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE; THYMECTOMY;

ANIMALS; ANTIBODY AFFINITY; ANTIGENS, CD44; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL CULTURE TECHNIQUES; FEMALE; INTERFERON TYPE II; INTRAMOLECULAR OXIDOREDUCTASES; LYMPHOMA, T-CELL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; RECEPTORS, INTERLEUKIN-2; SPLEEN; THYMUS GLAND; TUMOR CELLS, CULTURED;

EID: 0034798441     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2001.01278.x     Document Type: Article

References (31)

1. Cancer antigens: Immune recognition of self and altered self
2. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
3. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
4. The tyrosinase gene codes for an antigen recognized by autologous cytotoxic T lymphocytes on HLA-A2 melanomas
5. A new era for cancer immunotherapy based on the genes that encode cancer antigens
6. Tumor antigens recognized by T cells
7. Inducing autoimmune disease to treat cancer
8. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma
9. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
10. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2)
11. Characterization of B16 melanoma-specific cytotoxic T lymphocytes
12. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy
13. Specific recognition of thymic self-peptides induces the positive selection of cytotoxic T lymphocytes
14. Failure of T cell receptor Vβ negative selection in an athymic environment
15. Evidence for extrathymic generation of intermediate T cell receptor cells in the liver revealed in thymectomized, irradiated mice subjected to bone marrow transplantation
16. + lymphocytes reveals a major extrathymic pathway of T cell differentiation
17. Positive selection of extrathymically developed T cells by self-antigens
18. Gp100/pmel 17 is a murine tumor rejection antigen: Induction of 'self'-reactive, tumoricidal T cells using high-affinity, altered peptide ligand
19. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL
20. + T cells in various immune organs
21. Coupling and uncoupling of tumor immunity and autoimmunity
22. Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy
23. Activation of low avidity CTL specific for a self epitope resulted in tumor rejection but not autoimmunity
24. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells resulted in severe autoimmune disease
25. + T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals
26. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T-lymphocytes associated with in vivo tumor regression
27. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1 (27-35)
28. + T-cell clones reactive to melanoma/melanocyte epitope MART-1 27-35
29. TCR-independent activation of extrathymocally developed, self antigen-specific T cells by IL-2/IL-15
30. Anti-tumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogenous CTL response
31. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors